OXB (previously Oxford Biomedica)

OXB (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable our partners to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical, biotech and stealth companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, a location near Boston, MA, US, and two locations in France – one in Lyon and the other, in Strasbourg.

www.oxb.com